Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7491379 | 1.00 | CYP2D6 (0.52) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL7491387 | 1.00 | CYP2D6 (0.52) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL1153634 | 1.00 | CYP2D6 (0.52) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL295338 | 1.00 | CYP2D6 (0.52) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8841088 | 0.98 | CYP2D6 (0.50) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8841086 | 0.98 | CYP2D6 (0.50) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL5189952 | 0.90 | KIF11 (0.47) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL28813446 | 0.85 | KIF11 (0.48) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL301345 | 0.82 | ALDH1A1 (0.57) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 | |
| SCHEMBL6021075 | 0.82 | ALDH1A1 (0.57) | CYP2D6KDM4ELMNAALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130253061-A1 | METHOD OF DROXIDOPA SYNTHESIS | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | claimed |
| WO-2013142093-A1 | METHOD FOR THE SYNTHESIS OF DROXIDOPA | CHELSEA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | claimed |
| US-8471067-B2 | Stereoselective preparation of P-chiral four-co-ordinated phosphorus compound (o-Tolylphenylmethylphosphine oxide) by reacting chiral alcohol, chiral amine or chiral thiol, with P-chiral three-co-ordinated phosphorus compound, in presence of electrophile | UNIVERSITY COLLEGE DUBLIN (IE) | 2013-06-25 | — | — | US | claimed |
| US-20080255391-A1 | Chiral Phosphorus Compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND (IE) | 2008-10-16 | — | — | US | claimed |
| US-4562263-A | HYPOTENSIVE AND HYDERTENSIVE AGENTS, ANTIDEPRESSANTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-12-31 | — | — | US | claimed |
| EP-0128684-A1 | Process for producing 3-(3,4-dihydroxyphenyl) serine | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1984-12-19 | — | — | EP | claimed |
| EP-0112606-A1 | Threo-adrenalinecarboxylic acid, processes for the production thereof, and pharmaceutical compositions thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-07-04 | — | — | EP | claimed |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | TAMBO INC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119823023-A | Process for preparing functionalized cyclooctenes | 坦博公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113473975-B | Process for preparing functionalized cyclooctenes | 坦博公司 | 2025-01-21 | — | — | CN | disclosed |
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | TAMBO, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113549084-B | Method for stereoselectively synthesizing chiral lactone | 杭州科兴生物化工有限公司 | 2023-02-28 | — | — | CN | disclosed |
| EP-3374345-B1 | PROCESSES FOR THE PREPARATION OF DIASTEREOMERICALLY AND ENANTIOMERICALLY ENRICHED OXAZOLINES | QUIM SINTETICA S A (ES) | 2022-01-12 | — | — | EP | disclosed |
| EP-0112606-A1 | Threo-adrenalinecarboxylic acid, processes for the production thereof, and pharmaceutical compositions thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-07-04 | — | — | EP | disclosed |
| EP-0092194-A1 | Method of obtaining optically active half esters | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-10-26 | — | — | EP | disclosed |
| EP-0084892-A2 | Preparation of optically active cis-1,3-dibenzyl-hexahydro-1H-furo(3,4-d)imidazole-2,4-dione and its intermediates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-08-03 | — | — | EP | disclosed |
| EP-0075868-A2 | Optically active amino alcohols and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-04-06 | — | — | EP | disclosed |
| US-4325886-A | BY FORMING A SALT WITH A DIPHENYL HYDROXY AMINE COMPOUND, FRACTIONAL CRYSTALLIZATION, SEPARATION AND ACIDIFICATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-04-20 | — | — | US | disclosed |
| US-4319040-A | Process for the production of optically active threo-3-(3,4-dihydroxyphenyl)serine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-03-09 | — | — | US | disclosed |
| EP-0024210-A1 | Process for the production of optically active threo-3-(3,4-dihydroxyphenyl) serine, and product thus produced | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12194100-B2 | Processes for preparing functionalized cyclooctenes | PPOX, SCO2, CYCS | CYP2D6 139/4885KDM4E 4387/4885LMNA 3000/4885 |
| US-20130253061-A1 | METHOD OF DROXIDOPA SYNTHESIS | DDO, DAO, COMT | CYP2D6 376/4885KDM4E 3547/4885LMNA 4273/4885 |
| US-20080255391-A1 | Chiral Phosphorus Compounds | PHOSPHO1, PNKP, PTMS | CYP2D6 2590/4885KDM4E 4137/4885LMNA 3952/4885 |
| US-20250135005-A1 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | PPOX, SCO2, CYCS | CYP2D6 139/4885KDM4E 4387/4885LMNA 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.